S&P 500   4,237.99 (+0.73%)
DOW   33,478.71 (+0.43%)
QQQ   326.83 (+0.85%)
AAPL   170.45 (+1.16%)
MSFT   288.50 (+0.52%)
META   180.13 (+1.49%)
GOOGL   119.86 (+0.86%)
AMZN   140.70 (+0.04%)
TSLA   875.75 (+1.84%)
NVDA   184.46 (+2.81%)
NIO   20.71 (-0.53%)
BABA   92.99 (-1.98%)
AMD   100.64 (+2.57%)
MU   63.78 (+2.34%)
T   18.14 (+0.55%)
CGC   3.27 (+3.81%)
GE   78.84 (-0.08%)
F   16.00 (+1.07%)
DIS   120.49 (+2.38%)
AMC   25.71 (+0.98%)
PYPL   100.37 (+1.27%)
PFE   49.35 (+2.20%)
NFLX   245.20 (+1.03%)
S&P 500   4,237.99 (+0.73%)
DOW   33,478.71 (+0.43%)
QQQ   326.83 (+0.85%)
AAPL   170.45 (+1.16%)
MSFT   288.50 (+0.52%)
META   180.13 (+1.49%)
GOOGL   119.86 (+0.86%)
AMZN   140.70 (+0.04%)
TSLA   875.75 (+1.84%)
NVDA   184.46 (+2.81%)
NIO   20.71 (-0.53%)
BABA   92.99 (-1.98%)
AMD   100.64 (+2.57%)
MU   63.78 (+2.34%)
T   18.14 (+0.55%)
CGC   3.27 (+3.81%)
GE   78.84 (-0.08%)
F   16.00 (+1.07%)
DIS   120.49 (+2.38%)
AMC   25.71 (+0.98%)
PYPL   100.37 (+1.27%)
PFE   49.35 (+2.20%)
NFLX   245.20 (+1.03%)
S&P 500   4,237.99 (+0.73%)
DOW   33,478.71 (+0.43%)
QQQ   326.83 (+0.85%)
AAPL   170.45 (+1.16%)
MSFT   288.50 (+0.52%)
META   180.13 (+1.49%)
GOOGL   119.86 (+0.86%)
AMZN   140.70 (+0.04%)
TSLA   875.75 (+1.84%)
NVDA   184.46 (+2.81%)
NIO   20.71 (-0.53%)
BABA   92.99 (-1.98%)
AMD   100.64 (+2.57%)
MU   63.78 (+2.34%)
T   18.14 (+0.55%)
CGC   3.27 (+3.81%)
GE   78.84 (-0.08%)
F   16.00 (+1.07%)
DIS   120.49 (+2.38%)
AMC   25.71 (+0.98%)
PYPL   100.37 (+1.27%)
PFE   49.35 (+2.20%)
NFLX   245.20 (+1.03%)
S&P 500   4,237.99 (+0.73%)
DOW   33,478.71 (+0.43%)
QQQ   326.83 (+0.85%)
AAPL   170.45 (+1.16%)
MSFT   288.50 (+0.52%)
META   180.13 (+1.49%)
GOOGL   119.86 (+0.86%)
AMZN   140.70 (+0.04%)
TSLA   875.75 (+1.84%)
NVDA   184.46 (+2.81%)
NIO   20.71 (-0.53%)
BABA   92.99 (-1.98%)
AMD   100.64 (+2.57%)
MU   63.78 (+2.34%)
T   18.14 (+0.55%)
CGC   3.27 (+3.81%)
GE   78.84 (-0.08%)
F   16.00 (+1.07%)
DIS   120.49 (+2.38%)
AMC   25.71 (+0.98%)
PYPL   100.37 (+1.27%)
PFE   49.35 (+2.20%)
NFLX   245.20 (+1.03%)

Kezar Life Sciences - KZR Stock Forecast, Price & News

$10.34
+0.58 (+5.94%)
(As of 08/12/2022 10:57 AM ET)
Add
Compare
Today's Range
$10.19
$10.67
50-Day Range
$4.58
$10.49
52-Week Range
$4.30
$18.55
Volume
7,723 shs
Average Volume
810,876 shs
Market Capitalization
$624.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
98.1% Upside
$19.33 Price Target
Short Interest
Healthy
9.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.73mentions of Kezar Life Sciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.13) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

368th out of 1,112 stocks

Pharmaceutical Preparations Industry

184th out of 544 stocks

KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Kezar Life Sciences Price Performance

Shares of KZR opened at $9.76 on Friday. Kezar Life Sciences has a 1-year low of $4.30 and a 1-year high of $18.55. The stock has a market cap of $589.66 million, a PE ratio of -9.38 and a beta of 0.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 35.25 and a quick ratio of 35.25. The firm has a fifty day moving average price of $8.24 and a 200 day moving average price of $11.00.

Kezar Life Sciences (NASDAQ:KZR - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03. As a group, sell-side analysts anticipate that Kezar Life Sciences will post -1.13 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on KZR. Wells Fargo & Company lifted their price objective on shares of Kezar Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 28th. Jonestrading boosted their price target on shares of Kezar Life Sciences from $17.00 to $20.00 in a research report on Tuesday, June 28th.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

Why Kezar Life Sciences Stock Is Crushing It Today
After-Hours Action: Why Kezar Life Sciences Stock Is Soaring
Kezar Life Sciences Inc - Stock News
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings
11/09/2021
Today
8/12/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.33
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+90.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-54,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.01 per share

Miscellaneous

Free Float
55,764,000
Market Cap
$624.74 million
Optionable
Not Optionable
Beta
0.16

Key Executives

  • Mr. John Franklin Fowler (Age 49)
    Co-Founder, CEO & Director
    Comp: $905.06k
  • Dr. Christopher J. Kirk Ph.D. (Age 49)
    Co-Founder, Pres, Chief Scientific Officer & Director
    Comp: $658.81k
  • Dr. Noreen Roth Henig M.D. (Age 57)
    Chief Medical Officer
    Comp: $705.53k
  • Dr. Jack Taunton Ph.D.
    Co-Founder
  • Mr. Marc L. Belsky (Age 67)
    CFO & Sec.
  • Mr. Michael Wolfe
    VP of Fin. & Bus. Operations
  • Ms. Gitanjali Jain
    VP of Investor Relations & External Affairs
  • Mr. Mark Schiller
    Sr. VP of Legal Affairs
  • Dr. Neel K. Anand Ph.D.
    VP of Medicinal Chemistry & Head of Drug Discovery
  • Ms. Pattie Chiang
    VP & Corp. Controller













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KZR shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2022?

2 equities research analysts have issued 1-year price objectives for Kezar Life Sciences' stock. Their KZR share price forecasts range from $17.00 to $22.00. On average, they expect the company's stock price to reach $19.67 in the next year. This suggests a possible upside of 101.5% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2022?

Kezar Life Sciences' stock was trading at $16.72 at the beginning of the year. Since then, KZR shares have decreased by 41.6% and is now trading at $9.76.
View the best growth stocks for 2022 here
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) released its earnings results on Tuesday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (4.59%), Franklin Resources Inc. (2.26%), Deutsche Bank AG (0.50%), Connor Clark & Lunn Investment Management Ltd. (0.40%), Group One Trading L.P. (0.00%) and Russell Investments Group Ltd. (0.19%). Insiders that own company stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Michael Kauffman, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $9.76.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $589.66 million. The company earns $-54,630,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.